Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Quarterly results
ACELRX PHARMACEUTICALS INC (ACRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
10/05/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/05/2023 8-K Changes in Registrant's Certifying Accountant, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " "
08/25/2023 144 Form 144 - Report of proposed sale of securities:
08/24/2023 144 Form 144 - Report of proposed sale of securities:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update"
08/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/09/2023 424B7 Form 424B7 - Prospectus [Rule 424(b)(7)]:
08/02/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
07/31/2023 8-K Quarterly results
07/28/2023 D Form D - Notice of Exempt Offering of Securities:
07/21/2023 8-K Quarterly results
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update"
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
02/14/2023 SC 13G/A ARMISTICE CAPITAL, LLC reports a 10% stake in ACELRX PHARMACEUTICALS, INC.
12/29/2022 8-K Quarterly results
12/28/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/05/2022 8-K Quarterly results
11/23/2022 EFFECT Form EFFECT - Notice of Effectiveness:
11/22/2022 424B7 Form 424B7 - Prospectus [Rule 424(b)(7)]:
11/15/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
Docs: "AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update"
10/25/2022 8-K Quarterly results
09/23/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/17/2022 D Form D - Notice of Exempt Offering of Securities:
08/12/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/12/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/12/2022 8-K Quarterly results
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy